Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Connecticut Retirement v. Amgen Inc et al
Case Number:
2:07-cv-02536
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Barrack Rodos
- Berger Montague
- Berman Tabacco
- Glancy Prongay
- Hueston Hennigan
- Irell & Manella
- Kahn Swick
- Kohn Swift
- Labaton Keller
- Lieff Cabraser
- LimNexus
- Lockridge Grindal
- Mayer Brown
- Milberg Coleman
- Nelson & Fraenkel
- Robbins Geller
- Sheppard Mullin
- Stoll Keenon
- Stull Stull
- Susman Godfrey
- Zimmerman Reed
Companies
Sectors & Industries:
-
October 26, 2016
Labaton Secures $23.8M In Fees For Amgen Securities Deal
A California federal judge on Wednesday granted $23.8 million in attorneys' fees to Labaton Sucharow LLP and others serving as class counsel to investors who reached a $95 million settlement with Amgen Inc. over the company's alleged misstatements about two of its anti-anemia drugs.
-
July 20, 2016
Amgen To Pay $95M In Class Action Securities Settlement
Global biotechnology company Amgen Inc. has reached a $95 million settlement with investors over alleged misstatements about two of its anti-anemia drugs, according to settlement documents filed in California federal court Wednesday, bringing nearly a decade of class action litigation to a close.
-
November 08, 2011
9th Circ. Keeps Investor Class Intact In Anemia Drug Fight
The Ninth Circuit refused on Tuesday to decertify a class of shareholders in a case alleging Amgen Inc. misled investors about two top-selling anemia drugs, ruling the suit plausibly alleged the biotech company's statements were both false and material.